Incisive Genetics, a Vancouver BC-based held biotech company, raised $2.5M in seed funding.
The round was led by investors Noel Hall and Sandra MacPherson of the MacHall group and Haig Farris, OC.
The company intends to use the funds to develop its manufacturing process and capabilities, advance key studies to enhance its gene editing delivery platform technology, and further add to its intellectual property portfolio.
Established in 2018 and led by Dr. Blair R. Leavitt, Incisive Genetics provides a non-viral delivery platform for genetic therapies. This delivery platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company’s pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases.